144 related articles for article (PubMed ID: 12041852)
41. [Monoclonal gammopathies of undetermined significance].
Krizalkovicová V; Maisnar V; Pour L; Radocha J; Hájek R
Klin Onkol; 2008; 21(4):160-4. PubMed ID: 19102222
[TBL] [Abstract][Full Text] [Related]
42. [50-year-old man with fatigue and monoclonal gammopaty].
Raeder H; Kildahl-Andersen O; Stalsberg H
Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2677-9. PubMed ID: 17972388
[TBL] [Abstract][Full Text] [Related]
43. Prognostic factors in monoclonal gammopathy of undetermined significance.
Sackmann F; Pavlovsky MA; Corrado C; Pizzolato M; Alejandre M; Pavlovsky S
Haematologica; 2008 Jan; 93(1):153-4. PubMed ID: 18166806
[TBL] [Abstract][Full Text] [Related]
44. Malignant transformation in polyneuropathy associated with monoclonal gammopathy.
Eurelings M; Lokhorst HM; Kalmijn S; Wokke JH; Notermans NC
Neurology; 2005 Jun; 64(12):2079-84. PubMed ID: 15985576
[TBL] [Abstract][Full Text] [Related]
45. [Monoclonal gammopathies of undetermined significance].
Zandecki M; Geneviève F; Jego P; Grosbois B
Rev Med Interne; 2000 Dec; 21(12):1060-74. PubMed ID: 11191674
[TBL] [Abstract][Full Text] [Related]
46. The relationship between proliferation and apoptosis in patients with monoclonal gammopathy of undetermined significance or multiple myeloma.
Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Horak P; Minarik J
Haematologica; 2005 Dec; 90(12):1713-4. PubMed ID: 16330455
[TBL] [Abstract][Full Text] [Related]
47. Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance.
Bladé J; Filella X; Montoto S; Bosch F; Rosiñol L; Coca F; Giné E; Nadal E; Aymerich M; Rozman M; Montserrat E
Br J Haematol; 2002 May; 117(2):387-9. PubMed ID: 11972522
[TBL] [Abstract][Full Text] [Related]
48. Should bone marrow examination be routinely performed for the diagnosis of monoclonal gammopathy of undetermined significance?
Elis A; Radnay J; Shapiro H; Itzhaky D; Manor Y; Lishner M
Isr Med Assoc J; 2006 Dec; 8(12):840-2. PubMed ID: 17214099
[TBL] [Abstract][Full Text] [Related]
49. Monoclonal gammopathy of undetermined significance in sarcoidosis. Two case reports.
Sharma AM; Fried J; Sharma OP
Sarcoidosis; 1992 Mar; 9(1):70-2. PubMed ID: 1344048
[TBL] [Abstract][Full Text] [Related]
50. Malignant evolution of monoclonal gammopathy of undetermined significance: analysis of 633 consecutive cases with a long term follow-up.
Veneri D; Aqel H; Franchini M; Krampera M; Zanotti R; Pizzolo G
Haematologica; 2004 Jul; 89(7):876-8. PubMed ID: 15257948
[TBL] [Abstract][Full Text] [Related]
51. Fibrillary glomerulopathy secondary to light chain deposition disease in a patient with monoclonal gammopathy.
Sundaram S; Mainali R; Norfolk ER; Shaw JH; Zhang PL
Ann Clin Lab Sci; 2007; 37(4):370-4. PubMed ID: 18000296
[TBL] [Abstract][Full Text] [Related]
52. [Nephropathies in the course of plasma cell disorders].
Hanicki Z
Przegl Lek; 1995; 52(3):97-9. PubMed ID: 7644685
[No Abstract] [Full Text] [Related]
53. Peripheral neuropathies associated with monoclonal gammopathies of undetermined significance.
Kelly JJ
Rev Neurol Dis; 2008; 5(1):14-22. PubMed ID: 18418318
[TBL] [Abstract][Full Text] [Related]
54. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
55. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
Srkalovic G; Cameron MG; Rybicki L; Deitcher SR; Kattke-Marchant K; Hussein MA
Cancer; 2004 Aug; 101(3):558-66. PubMed ID: 15274069
[TBL] [Abstract][Full Text] [Related]
56. Rituximab failure in a patient with monoclonal gammopathy of undetermined significance (MGUS)-associated acquired von Willebrand syndrome.
Grimaldi D; Bartolucci P; Gouault-Heilmann M; Martin-Toutain I; Khellaf M; Godeau B
Thromb Haemost; 2008 Apr; 99(4):782-3. PubMed ID: 18392339
[No Abstract] [Full Text] [Related]
57. [The epidemiology of multiple myeloma].
Suzuki K; Takahashi H
Nihon Rinsho; 2015 Jan; 73(1):7-12. PubMed ID: 25626296
[TBL] [Abstract][Full Text] [Related]
58. [The CBO professional guideline 'monoclonal gammopathy' (paraproteinemia) (revision)].
Buiting AM; Wijermans PW
Ned Tijdschr Geneeskd; 2002 Jul; 146(30):1406-11. PubMed ID: 12174434
[TBL] [Abstract][Full Text] [Related]
59. [Soluble syndecan-1 levels in different plasma cell dyscrasias].
Jánosi J; Sebestyén A; Mikala G; Petö M; Jákó J; Domján G; Németh J; Kis Z; Kopper L; Vályi-Nagy I
Orv Hetil; 2005 Jan; 146(4):165-8. PubMed ID: 15751511
[TBL] [Abstract][Full Text] [Related]
60. Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status.
Yeh HS; Chen H; Manyak SJ; Swift RA; Campbell RA; Wang C; Li M; Lee HJ; Waterman G; Gordon MS; Ma J; Bonavida B; Berenson JR
Br J Haematol; 2006 Jun; 133(5):526-9. PubMed ID: 16681640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
